Navigation Links
ARIUS presents new findings for anti-cancer antibody programs at AACR
Date:4/15/2008

ng Trop-2.

A humanized version of this antibody has greater higher affinity than the murine version and will be used in a pre-clinical toxicology study. A cell line has been developed for the Trop-2 targeting antibody and it is currently in manufacturing to generate material for Phase I clinical studies.

CD59 Complement Inhibitor Program

A monoclonal antibody targeting CD59 (AR36A36.11.1), enhances complement activity and exhibits potent in vivo efficacy in multiple human cancer models. Abstract Number 3995. Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

ARIUS has expanded its expression profiling and has characterized the affinity for its CD59 targeting antibody, AR36A36.11.1. This antibody has demonstrated significant in vivo anti-tumor activity towards a broad range of high incidence cancers and is highly potent at low dose concentrations in tumor xenografts, comparing favorably to standard of care in breast and prostate cancer.

The effectiveness of this very potent antibody may be attributed to its ability to block CD59 function, representing a novel approach to cancer treatment. Currently, there are no other reported naked therapeutic antibodies targeting CD59 in clinical development.

A humanized version of ARIUS' CD59 targeting antibody demonstrated equivalent affinity and potency to the murine version, and a CHO cell line producing humanized AR36A36.11.1 has been generated to manufacture material for future clinical studies.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is develop
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ARIUS announces first quarter fiscal 2008 financial results
2. ARIUS 2008 Annual and Special Meeting of Shareholders
3. ARIUS recognized for entrepreneurial excellence
4. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
5. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
6. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
7. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
8. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
9. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
10. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
11. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2014)... The “Fluid Management & Visualization Systems ... market with an analysis and forecast of value ... fluid warming and waste management. Along with this, ... systems by applications and regions are also discussed ... at $19,285.5 million in 2013 and is expected ...
(Date:11/15/2014)... The redesigned ActiGraph Link expands upon ... measurement platform with a rich feature set that ... new channels of sensor data captured by a ... Smart technology, the ActiGraph Link supports wireless heart ... ActiGraph’s cloud-based Study Admin platform, giving academic and ...
(Date:11/15/2014)... The "Operating Room Management Market by Product ... Preoperative, operating room Scheduling), by Component (Software, Services), ... to 2019.” defines and segments the operating room ... value by product, such as data management, anesthesia, ... and volumes of operating room management market by ...
(Date:11/15/2014)... 2014 Algenol Biofuels will present at CleanEquity Monaco ... of Monaco . Logo - ... annual invitation-only event hosted by Innovator Capital, the ... partners and sponsors include Prince Albert II of ... University, PR Newswire, the Monte-Carlo SBM, Oceanographic Museum of ...
Breaking Biology Technology:Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 2Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 3Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 4ActiGraph Launches GT9X Link Activity Monitor 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 3Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 4Algenol Biofuels Selected to Present at CleanEquity Monaco 2015 2
... Nov. 7 Interleukin Genetics,Inc. (Amex: ILI ), ... and genetic tests for sale to the,emerging personalized health ... 30, 2007. The Company recorded revenue of $2.6 ... million for third quarter ended September 30,2006, a 92% ...
... Function and Tissue Preservation ... in Spinal Cord Injury Model, SAN DIEGO, Nov. ... today the presentation of preclinical data from,its ZFP Therapeutic(TM) ... Meeting of the Society for Neuroscience. A statistically,significant effect ...
... Nov. 7 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), ... of anti-adhesion, tissue repair and drug delivery,products, announced ... registration,statement with the Securities and Exchange Commission (SEC) ... SyntheMed to sell, from time to,time, up to ...
Cached Biology Technology:Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 2Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 3Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 4Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 5Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 6Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 2Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 3Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 4Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 5SyntheMed Files Universal Shelf Registration 2
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
(Date:11/4/2014)... Nov. 4, 2014   Neurotechnology , a ... that the latest version of its fingerprint matching ... Ongoing MINEX evaluation organized by NIST. The ... using the INCITS 378 fingerprint standard template format. ... public tenders in the United States ...
(Date:11/3/2014)... published in this month,s Proceedings of the ... a recently discovered communication molecule of the body,s immune ... to limit inflammation and the current study reports its ... ability of the immune system to recognize and target ... effect on the immune system now allows us to ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... who study HIV are facing a troubling consequence of their ... patients almost normal life expectancy. However, those same drugs will ... form that eludes current treatments. With a new $3.4 ... of Missouri is leading a team of researchers who want ...
... in the eye often are fatal. Now, scientists at Washington ... identified a mutated gene in melanoma tumors of the eye ... is published in the advance online edition of Nature ... SF3B1," says senior author Anne Bowcock, PhD, professor of genetics. ...
... TEMPE, Ariz.---Arizona State University,s Biodesign Institute has announced ... enters the next phase of a multi-million-dollar, multi-institutional ... rapidly assess an individual,s exposure to radiation in ... project enters a $9.33 million contract option as ...
Cached Biology News:Researchers attack HIV's final defenses before drug-resistant mutations emerge 2Researchers attack HIV's final defenses before drug-resistant mutations emerge 3Gene in eye melanomas linked to good prognosis 2ASU partners with Life Technologies on US DHHS funded project to rapidly assess radiation dose 2
... The CHEMICON® CaspaTag™ Caspase-9 Pan-Caspase In ... assay for detection of active caspases in ... research use only. Not for use in ... Situ Caspase Detection Kits use a novel ...
... The transformation of Saccharomyces cerevisiae, as ... routine procedure in many molecular biology laboratories. ... high efficiencies with plasmid and linear DNAs ... has made routine plasmid transformations and library ...
... a fluorescein-conjugated jetSI-ENDO (excitation ... 520 nm), the powerful siRNA ... used to determine the transfection ... delivery and trafficking of siRNAs. ...
... for high efficiency siRNA delivery ... reagent proven to work effectively ... cell types. Results in silencing ... target gene expression. One step, ...
Biology Products: